VIJAYPD (VIJAYPD) fundamentals

VIJAYPD is a listed company, part of the DVR sector, listed on the NSE as VIJAYPD (ISIN INE0WL901019). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.

What VIJAYPD does

VijayPD Ceutical Ltd is engaged in the business of distributing and supplying the pharmaceutical and consumer goods sectors. The Company provides a range of products, serving both the pharmaceutical and wellness industries, as well as the fast-moving consumer goods (FMCG) market, including pharmaceutical and wellness products such as medicines, including injections, tablets, capsules, ointments, suppositories, ophthalmic preparations, and liquid oral formulations. It also supplies vitamins, hormones, enzymes, wellness tonics, serums, and diagnostic test kits. The Company also provides personal care and toiletry products, including soaps, sanitizers, and baby care items. It also deals in ayurvedic products, cosmetics, food products, dental products, and crude drugs. The Company operates three distribution warehouses located in Mumbai. It delivers healthcare solutions to pharmacies, nursing homes, and clinics across Western Suburban Mumbai, South Mumbai, Ratnagiri, Aurangabad and Akola.

Valuation and market data

Last close₹65.00
Market capitalisation₹81 crore
Enterprise value₹79 crore
P/E (TTM)0.00
Price to book2.53
Price to sales (TTM)0.00
Book value per share₹25.74
Dividend yield0.00%
SectorDVR
Industry

Annual results

PeriodRevenueProfit before taxNet profitEPS
Mar 2026₹104 crore₹6 crore₹5 crore0.00

Figures are as reported (consolidated), in ₹ crore.

Shareholding pattern

As of Mar 2026:

Promoters56.4%
Foreign institutions (FII)0.0%
Mutual funds0.0%
Other domestic institutions0.0%
Retail and others43.6%

More on BreakPoint

FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.

Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.